BSECompany Update4 Nov 2026 · 4 Nov 2026, 06:34 pm
Intimation regarding execution of Agreement by Wholly Owned Subsidiary of the Company
Bacil Pharma Ltd · 524516
✦ AI SummaryExpansion
Bacil Pharma Ltd's wholly owned subsidiary, Bacil Research and Development Private Limited, has entered into an agreement with Efdee Pharma Private Limited for research and development activities relating to pharmaceutical products, with an estimated cost of ₹35,00,00,000.
Analysis Scores
Earnings Impact2/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Bacil Pharma Ltd - 524516 - Intimation Regarding Execution Of Agreement By Wholly Owned Subsidiary Of The Company
Attachments (1)
📄pdf
Download →
4c7a135e-2a59-4c0a-b8fe-0fb3bc2a7d7f.pdf
View document text
Reg Office: G2 & G3 Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai – 400099
Email Id: bacilpha@yahoo.com, CIN: L24200MH1987PLC043427, Tel: 22618452/22661541,
Tel/Fax: 22618327
Date: 04/11/2026
The Department of Corporate Services,
BSE Limited,
P. J. Towers, Dalal Street,
Mumbai – 400001.
Scrip Code: 524516
Scrip ID: BACPHAR
Subject: Intimation regarding execution of Agreement by Wholly Owned Subsidiary of
the Company
Dear Sir/Madam,
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, we wish to inform you that Bacil Research and Development Private
Limited, a wholly owned subsidiary of Bacil Pharma Limited (“the Company”), has entered
into an agreement with Efdee Pharma Private Limited for undertaking research and
development activities relating to pharmaceutical products.
The project shall involve research and development of pharmaceutical products, including
pellets, granules, powders, tablets and capsules.
The total estimated cost of the project shall be ₹35,00,00,000/- (Rupees Thirty Five Crore
Only).
In this regard, the Company has authorised Mrs. Chaitali Shah, Director, to execute the
aforesaid agreement and undertake all necessary acts, deeds and things, including signing and
executing documents and completing all formalities in connection with the said project on
behalf of the wholly owned subsidiary.
The details of the aforesaid transaction, as required under Regulation 30 of the SEBI (LODR)
Regulations, 2015, read with the applicable SEBI circulars, are enclosed as Annexure A.
You are requested to take the above information on record.
Thanking you,
Yours faithfully,
For Bacil Pharma Limited
Chaitali Kalpataru Shah
Managing Director
Din: 11167778
Reg Office: G2 & G3 Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai – 400099
Email Id: bacilpha@yahoo.com, CIN: L24200MH1987PLC043427, Tel: 22618452/22661541,
Tel/Fax: 22618327
Suggested Annexure A – Disclosure under Regulation 30
Particulars Details
Name of the entity entering into the Bacil Research and Development Private Limited
agreement
Relationship with the listed entity Wholly owned subsidiary of Bacil Pharma
Limited
Name of the other party Efdee Pharma Private Limited
Nature of agreement Agreement for research and development of
pharmaceutical products
Scope of project Research and development of pellets, granules,
powders, tablets and capsules
Estimated project cost ₹35,00,00,000/- (Rupees Thirty Five Crore Only)
Authorised representative Mrs. Chaitali Shah, Director
Date of agreement 04/11/2026
For Bacil Pharma Limited
Chaitali Kalpataru Shah
Managing Director
Din: 11167778